Of 65 ciprofloxacin-resistant, clinical isolates of Neisseria gonorrhoeae, 5 isolates exhibited ParC mutations previously undescribed in the gonococcus. For isolates containing two ParC mutations (the Ser-873Ile and Glu-913Gly mutations and the Gly-853Cys and Arg1163Leu mutations) the MICs of ciprofloxacin (8.0 to 64.0 g/ml) were higher than those for the isolate containing the single ParC mutation (Arg-1163Leu; MIC, 1.0 g/ml).
Fluoroquinolones are frequently used in the treatment of gonorrhea, with ciprofloxacin and ofloxacin used as primary treatment regimens in a number of countries. Recently, a number of gonococcal strains with decreased susceptibility or clinically significant resistance to the Centers for Disease Control and Prevention (CDC)-recommended doses of fluoroquinolones have been isolated (2, 11) . A number of studies have been performed to determine the mechanism of fluoroquinolone resistance in Neisseria gonorrhoeae (1, 3, 4, 6, 18, 19) . The most prevalent mechanisms contributing to fluoroquinolone resistance in the gonococcus involve mutations in the quinolone resistance-determining region of gyrA and the analogous region of the parC locus on the chromosome. These mutations result in altered GyrA and ParC proteins (1, 4, 6, 18) . These altered proteins can no longer be bound by the fluoroquinolone, and therefore, the drug is unable to inhibit DNA replication and the bacterium becomes less susceptible or resistant. The level of susceptibility appears to correlate to the location and number of mutations present (6) . This mechanism is analogous to those observed in Escherichia coli and other bacteria (9, 20) . However, unlike E. coli, mutations in the N. gonorrhoeae gyrB gene do not appear to have a significant impact on fluoroquinolone resistance (7), and no parE homolog has been described. have studied the effects that these mutations have on the level of fluoroquinolone resistance seen in various clinical gonococcal isolates. The mutations reported to date have occurred in amino acids Ser-91 and Asp-95 of GyrA and amino acid Asp-86, Ser-87, Ser-88, or Glu-91 of ParC. The order in which mutations occur and result in increased fluoroquinolone MICs for gonococcal strains follow a fairly predictable order: mutations in Ser-91 and/or Asp-95 of GyrA result in decreased susceptibility to ciprofloxacin (ciprofloxacin MICs, 0.125 to 0.5 g/ml). On the other hand, clinically significant resistance to CDC-recommended fluoroquinolone regimens (MIC, Ն1.0 g of ciprofloxacin per ml) appears to require one or more mutations in the ParC gene, in addition to both gyrA mutations. However, this order of mutations is not absolute and a number of gyrA and parC mutation patterns have been described. In this paper, we report the characterization of gonococcal isolates exhibiting clinically significant resistance to ciprofloxacin (MICs, 1.0 to 64.0 g/ml) in which the parC mutations differ either in number or in location from those described previously.
Eighty-three clinical isolates of N. gonorrhoeae were obtained from commercial sex workers during the course of a study on fluoroquinolone resistance in the Republic of the Philippines in 1996. All isolates exhibited decreased susceptibility to ciprofloxacin (MICs, Ն0.125 g/ml) and were characterized by auxotype, serovar, and antibiotic sensitivities as described previously (10, (12) (13) (14) 17) . Of these isolates, 65 were ciprofloxacin resistant (MIC range, 1.0 to 64.0 g/ml). The presence of gyrA and parC mutations was determined by PCR and restriction endonuclease reaction analysis as described by Deguchi et al. (5, 8) . Regions of gyrA and parC were amplified by PCR after extraction of the chromosomal DNA of each gonococcal strain. PCR amplification consisted of 35 cycles of denaturation at 94°C for 60 s, annealing at 52°C for 50 s, and extension at 72°C for 50 s in reaction aliquots of 50 l. Each PCR mixture contained 5 l of 10ϫ PCR buffer (Boehringer Mannheim, Indianapolis, Ind.), 1 l of a deoxynucleoside triphosphate stock solution (containing dATP, dCTP, dGTP, and dTTP each at a concentration of 10 mM; Boehringer Mannheim), 0.5 l of Taq DNA polymerase (5 units/l; Boehringer Mannheim), 2.5 l of each of the appropriate primers (1 mM), 28.5 l of sterile water, and 10 l of template DNA. PCR primers specific for gyrA and parC were the same as those described by Deguchi et al. (8) and were synthesized at the National Center for Infectious Diseases core facility at CDC in Atlanta, Ga. For each isolate 10 l of PCR product was restricted with endonuclease HinfI for gyrA or EcoRI, PstI, SalI, or HinfI for parC (Boehringer Mannheim) and was visualized after electrophoresis on a 6.5% polyacrylamide gel.
Of the 83 isolates characterized, five isolates ( Sequence analysis confirmed the presence of two mutations in the ParC genes of isolates RP96-70, RP96-c1-003, and RP96-c2-001 that corresponded to amino acid changes at Ser873Ile and Glu-913Gly. Sequence analysis of isolates RP96-46 and RP96-61 demonstrated the presence of mutations in parC that had not been described previously. Isolate RP96-46 contained a mutation which resulted in an amino acid change at position 116 from arginine to leucine. Isolate RP96-61 contained not only the mutation at position Arg-116 but also an additional mutation which caused an amino acid change at position 85 from glycine to cysteine. This is the first report of the presence of double ParC mutations identified in clinical isolates of N. gonorrhoeae. A double mutation was identified in a laboratory-induced resistant strain (1); the locations of the ParC mutations identified in this strain (Ser-88 and Gly-91) were different from the locations of the double mutations that we describe here. Additional examination of the three isolates containing the Ser-873Ile and Glu-913Gly ParC mutations suggest that they are not separate isolations of the same clone (Table 1) . RP96-70 was auxotype/serovar class PA/IB-1 and exhibited decreased susceptibility or resistance to penicillin and tetracycline (CMRx), while RP96-c1-003 was PA/IB-32 (penicillinase-producing N. gonorrhoeae [PPNG] ) and RP96-c2-001 was PA/IB-1 (PPNG). The other two isolates in this study present a different scenario. Isolates RP96-46 and RP96-61 belonged to auxotype/serovar class Proto/IB-1 and were PPNG. RP96-46, for which the ciprofloxacin MIC was 1.0 g/ml, contained only the mutation Arg-1163Leu. In contrast, RP96-61 contained the Gly853Cys mutation in addition to the Arg-1163Leu mutation, and the ciprofloxacin MIC for this strain was 16.0 g/ml. Acknowledging that transformation studies need to be performed for confirmation, these results suggest that the Arg-1163Leu mutation alone may be sufficient to produce clinically significant resistance (ciprofloxacin MIC, 1.0 g/ml) but that the addition of the Gly-853Cys mutation is necessary for the highlevel MICs for RP96-61 (ciprofloxacin MIC, 16.0 g/ml).
In summary, we have identified five ciprofloxacin-resistant isolates of N. gonorrhoeae that contain novel mutation patterns in parC, including two double mutations, the Ser-873Ile and Glu-913Gly mutations and the Gly-853Cys and Arg1163Leu mutations. Of these mutations, the Gly-853Cys and Arg-1163Leu mutations in parC have not been previously observed in the gonococcus. The importance of the double parC mutations appears to be the high-level ciprofloxacin resistance exhibited by the isolates which contain them. All four isolates which possess parC double mutations have high-level resistance to ciprofloxacin (MICs, 8.0 to 64.0 g/ml), whereas for the isolate with a single parC mutation the ciprofloxacin a All isolates contained GyrA mutations at Ser-91 and Asp-95. Abbreviations: Cip, ciprofloxacin; A/S, auxotype/serovar; Ser, serine; Glu, Glutamine; Gly, glycine; Arg, arginine; P, proline-requiring; A, arginine-requiring; Proto, no requirement for proline, arginine, hypoxanthine, uracil, or methionine; CMRx, strain for which the penicillin MIC was 2 g/ml and the tetracycline MIC was 1 g/ml (15, 16) ; PPNG, penicillinase-producing N. gonorrhoeae; Pen, penicillin; Tet, tetracycline.
b Wild-type amino acid(s) followed by the amino acid(s) resulting from the mutation. The corresponding nucleotide codon sequence is directly below each amino acid.
MIC was 1.0 g/ml. That the three strains that contain the Ser-873Ile and Glu-913Gly double mutations have different levels of ciprofloxacin resistance is not unexpected. For strains which contain the same mutation pattern with a single ParC mutation, a similar wide, although lower, range of MICs has been demonstrated (unpublished data). We speculate that the presence of double ParC mutations facilitates the high ciprofloxacin MICs for a strain, but the MIC may also be influenced by other characteristics of the strain.
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